A total of 92 Equity Offering deals (pending and completed) were announced in the Pharmaceuticals of Canada, in the last twelve months resulting in a total deal value of over $2,399.8 million. In the LTM period, October 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $471.3 million, resulting in an average deal value of $67.3 million during that month. On the other hand, the month of March 2022 was the most prolific in terms of deal volume, recording a total of 14 deals, resulting in an average deal value of $24.2 million during that month.
Of the 92 deals, the deal secured between 1315 Capital II LP; BioStar Capital; Greybrook Health Inc; Masters Special Situations LLC and Greenbrook TMS Inc., was the largest Equity Offering deal in the Canada Pharmaceuticals sector, which was valued at $23.5 million and was completed on June 14, 2021. The second-largest deal was between Evotec SE and Sernova Corp, while the third-largest deal was between Cannvalate Pty Ltd and Tetra Bio-Pharma Inc. The Evotec SE-Sernova Corp deal and the Cannvalate Pty Ltd-Tetra Bio-Pharma Inc deal were valued at $20.8 million and $5.9 million, respectively. The fourth-largest deal was between Chrystal Capital Partners LLP-Albert Labs Inc valued at $3.7 million, whereas the deal between Jerzy Wilczewski-Helix BioPharma Corp valued at $1.6 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $55.4 million and accounted for nearly 2.31% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward